Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparability Trial of MVA-BN Vaccine Manufactured in Different Production Cells for Mpox
NCT07199569Phase 2Active, not recruiting
- Sponsor
- Bavarian Nordic
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JYNNEOS in mpox (2 arms), sponsored by Bavarian Nordic. Primary endpoints: Immunogenicity of 2 doses of MVA-BN, Number of Participants with Serious Adverse Events up to 7 months and 6 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
JYNNEOS
03
Conditions
mpox
Beyond the preview
Go deeper on NCT07199569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199569.